Memory Treatment Centers

What Memory Treatment Centers does

Memory Treatment Centers is a private outpatient healthcare provider specializing in the diagnosis and treatment of Alzheimer's disease and related dementias. The company operates four clinics across the Southeast United States—Bonita Springs FL, Jacksonville FL, Dunwoody GA, and Marietta GA—and is a subsidiary of Pure Healthcare, LLC, a Utah-based parent organization. It focuses on administering disease-modifying anti-amyloid infusion therapies, including Leqembi (lecanemab) and Kisunla (donanemab), and was among the first U.S. clinics to administer Leqembi following its February 2023 FDA accelerated approval.

The company's clinical approach is biomarker-driven, integrating advanced diagnostics such as Oxford Brain Diagnostics' Dx p-tau 217 blood test (partnership announced September 2024), the Craniometrix GUIDE cognitive assessment program, and AI-driven analytics from Century Health (partnership announced November 2025). This diagnostic stack supports earlier detection and more precise treatment selection for Alzheimer's pathology. The company generates revenue primarily through insurance reimbursement and self-pay arrangements for infusion therapies, with Leqembi carrying an approximate annual self-pay cost of $26,500 per patient. It serves individual Alzheimer's and dementia patients and their families, targeting a structural addressable market projected to reach approximately 13 million Americans by 2050. Current operational scale is modest, with the Wall Street Journal reporting the company was treating 'dozens of patients'—indicating the business is in an early scaling phase rather than at steady-state throughput.

Name

Memory Treatment Centers

Legal name

Memory Treatment Centers

Website

https://memorytreatmentcenters.com

Company type

Private

Operating status

Operating

Headcount range

1–10 employees

Short description

Memory Treatment Centers is a private outpatient healthcare provider operating four Alzheimer's and dementia specialty clinics in Florida and Georgia, delivering biomarker-driven diagnosis and anti-amyloid infusion therapies including Leqembi and Kisunla.

Ownership category

akta.pro rank

Product category

Neurology and Alzheimer's Disease Specialty Care

NAICS

Services for the Elderly and Persons with Disabilities (624120)

SIC

Services-Offices & Clinics Of Doctors Of Medicine (8011), Services-Health Services (8000), Services-Specialty Outpatient Facilities, Nec (8093)

akta.pro primary industry

Cognitive & Behavioral Neurology (Dementia/Memory Disorders) (HLAKAIAH)

akta.pro secondary industries

Dementia/Alzheimer’s Care Management & Behavioral Support (HLADALAF), Memory Care Care Management & Navigation (Dementia Care Coordination) (HLADACAJ)

Keywords

• Alzheimer's disease treatment
• Cognitive impairment diagnosis
• Anti-amyloid infusion therapy
• Neurocognitive specialty care
• Memory disorder clinics

Headquarters

HQ city

Bonita Springs

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Healthcare Services: Revenue generated from patient consultations, diagnostic evaluations, and ongoing treatment services for cognitive impairment and Alzheimer's disease. Services include office visits, neuropsychological assessments, and IV infusions of FDA-approved anti-amyloid therapies. Medicare, Medicaid, and commercial insurance accepted.
2. Anti-Amyloid Therapy Infusions: IV infusion services for Leqembi (Lecanemab) and Kisunla (Donanemab) treatments. Leqembi self-pay cost is approximately $26,500/year (~$2,209/month) with patient assistance programs available. CMS covers Donanemab treatment under Medicare.
3. GUIDE Program Services: Partnership with Craniometrix to deliver Medicare-funded GUIDE program services supporting unpaid caregivers of dementia patients, including respite care, care coordination, and caregiver education.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Memory Treatment Centers provides specialized clinical services for the diagnosis and treatment of cognitive impairment and Alzheimer's disease. Core offerings include comprehensive neurocognitive evaluations (neuropsychological assessments, amyloid PET imaging, CSF and blood-based biomarker testing) and IV infusion administration of FDA-approved anti-amyloid therapies (Leqembi/Lecanemab bi-weekly, Kisunla/Donanemab monthly), delivered by board-certified neurologists and neurocognitive specialists across Florida and Georgia clinics with telehealth reach.

Product overview

Memory Treatment Centers operates as a neurocognitive disease clinic providing a unified care platform centered on Alzheimer's and dementia treatment. The core offerings include two FDA-approved anti-amyloid drug therapies—Leqembi (Lecanemab) administered bi-weekly and Kisunla (Donanemab) administered monthly—supported by neurocognitive evaluations using PET imaging, CSF analysis, and blood biomarkers. The platform integrates the GUIDE Medicare caregiver support program as a care coordination module, and employs Oxford Brain Diagnostics' Cortical Disarray Measurement technology for advanced neuroimaging analysis. Telehealth services extend patient access nationally. All services are delivered through board-certified neurologists and neurocognitive specialists at clinic locations in Florida and Georgia.

Differentiator

Problem solved

Functional benefit

Products and services

• Neurocognitive Evaluations Comprehensive diagnostic assessments for cognitive impairment, including neuropsychological evaluations, amyloid PET scans, cerebrospinal fluid analysis, and blood-based biomarkers, used to identify root causes of Alzheimer's disease and other dementias in adult patients.
• Leqembi (Lecanemab) Infusion Therapy FDA-approved disease-modifying anti-amyloid IV infusion therapy administered bi-weekly to qualified patients with mild cognitive impairment or mild Alzheimer's disease dementia, targeting beta-amyloid 42 plaques and demonstrated to slow cognitive decline by 27% in clinical trials.
• Kisunla (Donanemab) Infusion Therapy FDA-approved anti-amyloid IV infusion therapy administered monthly to patients with early symptomatic Alzheimer's disease, targeting beta-amyloid 42 plaques; demonstrated up to 35% slowing of cognitive and functional decline at 18 months in clinical trials, with limited-duration treatment based on plaque removal.
• GUIDE Program Caregiver Support Services Medicare-funded program providing comprehensive assessment, personalized care planning, medication management, 24/7 helpline access, caregiver education, support groups, and up to 80 hours per year of in-home respite care to unpaid caregivers of dementia patients, delivered in partnership with Craniometrix.
• Telehealth Neurocognitive Evaluations Virtual neurocognitive evaluations that allow adults suffering from MCI or potentially qualifying for Leqembi to undergo specialist assessment remotely from anywhere in the United States, expanding access beyond the physical clinic footprint.

Quantifiable outcome

• Leqembi (Lecanemab) demonstrated 27% slowing of cognitive decline compared to placebo in clinical trials
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature3 records

Partnerships

Four partnerships are on record, tiered core.

• Century HealthcoreStrategic or Co-development Partner · 13 November 2025Partnership announced to transform unstructured clinical data into research-grade real-world evidence for Alzheimer's disease care using AI. The initiative aims to analyze treatment outcomes and safety across diverse patient populations using an AI model developed by Century Health.
• Oxford Brain DiagnosticscoreStrategic or Co-development Partner · 9 September 2024Research collaboration to explore Alzheimer's disease in subjects who are cognitively impaired and receiving anti-amyloid treatment. MTC providers Dr. Don McCarren and Dr. Jamie Plante collaborate with OBD using Cortical Disarray Measurement (CDM) technology to assess brain regions impacted by neurodegenerative conditions and quantify neurodegeneration. The partnership aims to contribute HIPAA-compliant real-world data to the global neurologic community and advance understanding of Alzheimer's disease and its treatment.
• CraniometrixcoreStrategic or Co-development PartnerPartnership to deliver the GUIDE (Guiding an Improved Dementia Experience) program, a Medicare-funded program providing support to unpaid caregivers of dementia patients. Craniometrix provides caregiver support services including up to 80 hours/year of respite care, 24/7 helpline access, caregiver education, and support groups. MTC continues to provide all medical care for patients.
• Pure HealthcarecoreOthersMemory Treatment Centers is a Pure Healthcare Company. Pure Healthcare provides management services and operational support, including compliance, billing, and administrative functions. Pure Healthcare is expressly committed to not interfering with medical decisions made by licensed professionals.

Scale indicators4 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Quest Diagnostics: National clinical laboratory offering blood-based biomarkers and CSF analysis for Alzheimer's diagnosis, overlapping with MTC's biomarker testing capabilities. Comparable as a potential partner or alternative diagnostic channel for cognitive assessments.
• Biogen: Co-developer of Leqembi (Lecanemab) with Eisai and a major player in Alzheimer's therapeutics. Comparable as the upstream manufacturer of MTC's flagship infusion product and a key determinant of MTC's drug access and pricing economics.
• Eli Lilly: Manufacturer of Kisunla (Donanemab), the second FDA-approved anti-amyloid therapy that MTC administers monthly. Comparable as a key pharma counterparty shaping MTC's drug access and CMS coverage dynamics.
• Laboratory Corporation of America (Labcorp): Large diagnostics company offering CSF analysis, blood-based biomarkers, and specialty neurology testing. Comparable to MTC in providing diagnostic infrastructure that supports Alzheimer's diagnosis and staging decisions.
• Eisai: Manufacturer and commercializer of Leqembi and primary distributor of patient assistance programs that materially reduce out-of-pocket costs for MTC patients. Central counterparty to MTC's main revenue stream.

Direct peers

• US Neurology Partners: Multi-site neurology specialty practice platform offering comprehensive neurology services across multiple states. Operates a similar clinic-network model focused on neurology care delivery, comparable in structure and GTM to MTC's multi-clinic footprint.
• Cleveland Clinic Lou Ruvo Center for Brain Health: Multi-site specialty clinic network dedicated to Alzheimer's disease and other neurodegenerative disorders, offering diagnostic evaluations, clinical trials, and patient care. Closely comparable to MTC's specialty memory clinic model and disease-modifying therapy administration focus.
• Banner Alzheimer's Institute: Tertiary Alzheimer's disease research and treatment center with clinical care, biomarker testing, and disease-modifying therapy programs. Operates a similar specialty memory care delivery model with both clinical and research dimensions, much like MTC.

Emerging players

• Linus Health: Digital cognitive assessment platform using AI to detect early signs of cognitive impairment. Comparable as an emerging alternative or complement to MTC's in-person neurocognitive evaluations, with potential to extend screening reach.
• C2N Diagnostics: Developer of PrecivityAD, a blood-based biomarker test for amyloid pathology that supports Alzheimer's diagnosis. Comparable as an emerging diagnostic partner or alternative to PET/CSF-based testing used by MTC.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

• Facebookfacebook.com/Memorytreatmentcenters
• LinkedInlinkedin.com/company/memory-treatment-centers

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Memory Treatment Centers